Creating new tools to study membrane proteins for drug discovery
Engineered Nanodiscs for Structural Mass Spectrometry
This study is working on new tiny devices that can create special structures called lipid nanodiscs to help scientists better understand important proteins in our bodies that affect how drugs work, which could lead to better treatments for various conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10695919 on NIH RePORTER |
What this research studies
This research focuses on developing advanced microfluidic devices that can produce lipid nanodiscs with customizable compositions. These nanodiscs will be used to enhance structural mass spectrometry and proteomics assays specifically for membrane proteins, which are crucial for drug discovery. By improving our understanding of these proteins, particularly cytochrome P450, the research aims to uncover how they metabolize various drugs, potentially leading to new treatment strategies. The approach combines innovative technology with biophysical analysis to address significant gaps in current biomedical knowledge.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve drug metabolism or those who may benefit from new therapeutic strategies targeting membrane proteins.
Not a fit: Patients with conditions unrelated to drug metabolism or those not requiring new drug therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved drug discovery processes and more effective treatments for patients.
How similar studies have performed: Other research has shown promise in using similar approaches to study membrane proteins, indicating potential for success in this area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Ruotolo, Brandon T — University of Michigan at Ann Arbor
- Study coordinator: Ruotolo, Brandon T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.